Ribozymes for treating hepatitis C

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435 9131, 4353201, 435366, 435370, 536 231, 536 245, C07H 2104, C12Q 168, C12N 1563, A61K 4800

Patent

active

061070289

ABSTRACT:
A method of inhibiting hepatitis C virus RNA replication or expression is provided. The method consists of introducing two or more ribozymes specific for hepatitis C virus RNA into a cell infected with hepatitis C virus. The ribozymes specific for hepatitis C virus RNA can specifically cleave hepatitis C RNA in a HCV 5' non-coding sequence, the capsid sequence, the NS-5 sequence or any other conserved region of the hepatitis C RNA. The ribozymes can also be selected so as to be specific for opposite strands of the virus genome. A method of inhibiting hepatitis C virus RNA replication or expression is also provided which consists of introducing into a cell infected with hepatitis C virus at least one ribozyme specific for hepatitis C virus which is selected from the group consisting of GGGAGGTCTCGTAGA [SEQ ID NO: 1], GCACCATGAGCACGA [SEQ ID NO: 2], CCCACAGGACGTCAA [SEQ ID NO: 3], CAACCGTCGCCCACA [SEQ ID NO: 4], TAAACCTCAAAGAAA [SEQ ID NO: 5] GTAAGGTCATCGATA [SEQ ID NO: 6]. Compositions consisting of two or more ribozymes specific for hepatitis C virus RNA is also provided.

REFERENCES:
patent: 4861719 (1989-08-01), Miller
patent: 4987071 (1991-01-01), Cech et al.
patent: 5124263 (1992-06-01), Temin et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5354855 (1994-10-01), Cech et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5610054 (1997-03-01), Drapes et al.
Grundmann et al., Liver Regeneration After Experimental Injury Lesch & Reuter (eds.), NY: Stratton Intercontinental Medical Book Co. (1973).
Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P is the Catalytic Subunit of the Enzyme," Cell 35:849 (1983).
Hampel et al., "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," Biochem. 28:4929-4933 (1989).
Hampel et al., "`Hairpin` Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," Nucl. Acids Res. 18(2):299-304 (1990).
Heckel et al., "Neonatal Bleeding in Transgenic Mice Expressing Urokinase-Type Plasminogen Activator," Cell 62:447-456 (1990).
Hofmann et al., "Efficient Gene Transfer into Human Hepatocytes by Baculorivus Vectors," Proc. Natl. Acad. Sci. USA 92:10099-10103 (1995).
Kay et al., "Hepatic Gene Therapy: Persistent Expression of Human .alpha.1-Antitrypsin in Mice after Direct Gene Delivery In Vivo," Hum. Gene Ther. 3:641-647 (1992).
Kay et al., "In vivo Hepatic Gene Therapy: Complete Albeit Transient Correction of Factor IX Deficiency in Hemophilia B Dogs," Proc. Natl. Acad. Sci. USA 91:2353-2357 (1994).
Kay et al., "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," Sci. 262:117-119 (1993).
Ledley et al., "Hepatic Gene Therapy: Present and Future," Hepatol. 18(5):1263-1273 (1993).
Li et al., "Assessment of Recombinant Adenoviral Vectors for Hepatic Gener Therapy," Human Gene Ther. 4:403-409 (1993).
Miller, "Progess Toward Human Gene Therapy," Blood 76:271-278 (1990).
Miller et al., "Gene Transfer by Retrovirus Vectors Occurs Only in Cells That are Actively Replicating at the Time of Infection," Mol. Cell. Biol. 10:4239-4242 (1990).
Miller, "Human Gene Therapy Comes of Age," Nature 357:455-460 (1992).
Nagai et al., "Molecular Cloning of cDNA Coding for Human Preprourokinase," Gene 36:183-188 (1985).
Okamoto et al., "Full-Length Sequence of a Hepatitis C Virus Genome Having Poor Homology to Reported Isolates: Comparative Study of Four Distinct Genotypes," Virol. 188:331-341 (1992).
Pelham, "Evidence that Luminal ER Proteins are Sorted From Secreted Proteins in a Post-ER Compartment," EMBO J. 7:913-918 (1988).
Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis .delta. Virus RNA Sequence," Biochem. 31:16-21 (1992).
Pozzato et al., "Different Genotypes of Hepatitis C Virus are Associated With Different Severity of Chronic Liver Disease," J. Med. Virol. 43:291-296 (1994).
Rhim et al., "Replacement of Diseased Mouse Liver by Hepatic Cell Transplantation," Sci. 263:1149-1152 (1994).
Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," AIDS Res. Hum. Retrovir. 8:183 (1992).
Sandgren et al., "Complete Hepatic Regeneration After Somatic Deletion of an Albumin-Plasminogen Activator Transgene," Cell 66:245-256 (1991).
Schutze et al., "An N-terminal Double-Arginine Motif Maintains Type II Membrane Proteins in the Endoplasmic Reticulum," EMBO J. 13:1696-1705 (1994).
Shenk et al., "Genetic Analysis of Adenoviruses," Curr. Top. Microbiol. Immunol. 111:1-39 (1984).
Stratford-Perricaudet et al., "Widespread Long-term Gene Transfer to Mouse Skeletal Muscles and Heart," J. Clin. Invest. 90:626-630 (1992).
Strubin et al., "Two Forms of the Ia Antigen-Associated Invariant Chain Result from Alternative Initiations at Two In-Phase AUGs," Cell 47:619-625 (1986).
Yang et al., "Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for Gene Therapy," Proc. Natl. Acad. Sci. USA 91:4407-4411 (1994).
Yoshioka et al., "Detection of Hepatitis C Virus by Polymerase Chain Reaction and Response to Interferon-.alpha. Therapy: Relationship to Genotypes of Hepatitis C Virus," Hepatol. 16:293-299 (1992).
Barr et al., "Strain Related Variations in Adenovirally Mediated Transgene Expression from Mouse Hepatocytes In Vivo: Comparisons Between Immunocompetent and Immunodeficient Inbred Strains," Gene Ther. 2:151-155 (1995).
Cech, "Ribozyme Engineering," Curr. Op. Structural Biol. 2:605-609 (1992).
Fausto, "Hepatocyte Differentiation and Liver Progenitor Cells," Curr. Op. Cell Biol. 2:1096-1042 (1990).
Frankel (ed.), Genetically Engineered Toxins, Marcel Dekker, Inc. (1992).
Gorlich et al., "A Protein of the Endoplasmic Reticulum Involved Early in Polypeptide Translocation," Nature 357:47-52 (1992).
Grable et al., "cis and trans Requirements for the Selective Packaging of Adenovirus Type 5 DNA," J. Virol. 66:723-731 (1992).
Graham and Prevec, "Manipulation of Adenovirus Vectors," Methods in Molecular Biology: Gene Transfer and Expression Protocols, The Humana Press 7:109-128 (1991).
Stull et al. Pharm Res 12:465-483 (1995).
Sokol et al. Transgenic Research 5:363-371 (1996).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Ribozymes for treating hepatitis C does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ribozymes for treating hepatitis C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribozymes for treating hepatitis C will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-578986

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.